Clinical pathways in chronic lymphocytic leukemia: Challenges and solutions.

Chadi Nabhan, Gordana Raca, Y. Lynn Wang, Predicting Prognosis in Chronic Lymphocytic Leukemia in the Contemporary Era JAMA Oncology. ,vol. 1, pp. 965- 974 ,(2015) , 10.1001/JAMAONCOL.2015.0779

Sabine Ponader, Jan A. Burger, Bruton's Tyrosine Kinase: From X-Linked Agammaglobulinemia Toward Targeted Therapy for B-Cell Malignancies Journal of Clinical Oncology. ,vol. 32, pp. 1830- 1839 ,(2014) , 10.1200/JCO.2013.53.1046

Anthony Mato, Shekeab Jauhari, Stephen J. Schuster, Management of chronic lymphocytic leukemia (CLL) in the era of B-cell receptor signal transduction inhibitors American Journal of Hematology. ,vol. 90, pp. 657- 664 ,(2015) , 10.1002/AJH.24021

Tait Shanafelt, Treatment of older patients with chronic lymphocytic leukemia: key questions and current answers Hematology. ,vol. 2013, pp. 158- 167 ,(2013) , 10.1182/ASHEDUCATION-2013.1.158

Tait D. Shanafelt, Susan M. Geyer, Neil E. Kay, Prognosis at diagnosis: integrating molecular biologic insights into clinical practice for patients with CLL. Blood. ,vol. 103, pp. 1202- 1210 ,(2004) , 10.1182/BLOOD-2003-07-2281

Richard R. Furman, Jeff P. Sharman, Steven E. Coutre, Bruce D. Cheson, John M. Pagel, Peter Hillmen, Jacqueline C. Barrientos, Andrew D. Zelenetz, Thomas J. Kipps, Ian Flinn, Paolo Ghia, Herbert Eradat, Thomas Ervin, Nicole Lamanna, Bertrand Coiffier, Andrew R. Pettitt, Shuo Ma, Stephan Stilgenbauer, Paula Cramer, Maria Aiello, Dave M. Johnson, Langdon L. Miller, Daniel Li, Thomas M. Jahn, Roger D. Dansey, Michael Hallek, Susan M. O'Brien, Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. The New England Journal of Medicine. ,vol. 370, pp. 997- 1007 ,(2014) , 10.1056/NEJMOA1315226

John C. Byrd, Richard R. Furman, Steven E. Coutre, Ian W. Flinn, Jan A. Burger, Kristie A. Blum, Barbara Grant, Jeff P. Sharman, Morton Coleman, William G. Wierda, Jeffrey A. Jones, Weiqiang Zhao, Nyla A. Heerema, Amy J. Johnson, Juthamas Sukbuntherng, Betty Y. Chang, Fong Clow, Eric Hedrick, Joseph J. Buggy, Danelle F. James, Susan O'Brien, Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia The New England Journal of Medicine. ,vol. 369, pp. 32- 42 ,(2013) , 10.1056/NEJMOA1215637

Valentin Goede, Kirsten Fischer, Raymonde Busch, Anja Engelke, Barbara Eichhorst, Clemens M. Wendtner, Tatiana Chagorova, Javier de la Serna, Marie-Sarah Dilhuydy, Thomas Illmer, Stephen Opat, Carolyn J. Owen, Olga Samoylova, Karl-Anton Kreuzer, Stephan Stilgenbauer, Hartmut Döhner, Anton W. Langerak, Matthias Ritgen, Michael Kneba, Elina Asikanius, Kathryn Humphrey, Michael Wenger, Michael Hallek, Obinutuzumab plus Chlorambucil in Patients with CLL and Coexisting Conditions The New England Journal of Medicine. ,vol. 370, pp. 1101- 1110 ,(2014) , 10.1056/NEJMOA1313984

Jonas A. de Souza, Colleen Kelly, Chadi Nabhan, The Future of Cancer Care: Are We Ready For Personalized Value? Journal of The National Comprehensive Cancer Network. ,vol. 13, pp. 1049- 1051 ,(2015) , 10.6004/JNCCN.2015.0124

Philip A. Thompson, Susan M. O'Brien, William G. Wierda, Alessandra Ferrajoli, Francesco Stingo, Susan C. Smith, Jan A. Burger, Zeev Estrov, Nitin Jain, Hagop M. Kantarjian, Michael J. Keating, Complex karyotype is a stronger predictor than del(17p) for an inferior outcome in relapsed or refractory chronic lymphocytic leukemia patients treated with ibrutinib-based regimens Cancer. ,vol. 121, pp. 3612- 3621 ,(2015) , 10.1002/CNCR.29566